A comprehensive view of ISR Immune System Regulation Holding AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Gerresheimer signs agreement with drug development firm ISR for large-scale production of IcoOne nasal inhaler for ISR’s Phase 3 study of its dry powder COVID-19 vaccine; Gerresheimer has annual production capacity of more than 100 million inhalers
Published: June 02, 2022 by Gerresheimer AG
Ask us about our Health Care Sector market view